PERSPECTIVE

Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits

E Beurel1,2 and RS Jope1,2

Suicide is one of the leading causes of death in the United States, yet it remains difficult to understand the mechanistic provocations and to intervene therapeutically. Stress is recognized as a frequent precursor to suicide. Psychological stress is well established to cause activation of the inflammatory response, including causing neuroinflammation, an increase of inflammatory molecules in the central nervous system (CNS). Neuroinflammation is increasingly recognized as affecting many aspects of CNS functions and behaviors. In particular, much evidence demonstrates that inflammatory markers are elevated in traits that have been linked to suicidal behavior, including aggression, impulsivity and depression. Lithium is recognized as significantly reducing suicidal behavior, is anti-inflammatory and diminishes aggression, impulsivity and depression traits, each of which is associated with elevated inflammation. The anti-inflammatory effects of lithium result from its inhibition of glycogen synthase kinase-3 (GSK3). GSK3 has been demonstrated to strongly promote inflammation, aggressive behavior in rodents and depression-like behaviors in rodents, whereas regulation of impulsivity by GSK3 has not yet been investigated. Altogether, evidence is building supporting the hypothesis that stress activates GSK3, which in turn promotes inflammation, and that inflammation is linked to behaviors associated with suicide, including particularly aggression, impulsivity and depression. Further investigation of these links may provide a clearer understanding of the causes of suicidal behavior and provide leads for the development of effective preventative interventions, which may include inhibitors of GSK3.

Translational Psychiatry (2014) 4, e488; doi:10.1038/tp.2014.129; published online 16 December 2014

INTRODUCTION

In 2010, suicide was the 10th leading cause of death in the United States, accounting for more than 38,000 deaths, the suicide rate increased steadily during the previous 10 years, and an astounding approximately one million people in the US made a suicide attempt (Centers for Disease Control and Prevention website). Thus, it is evident that suicide is a major health problem that is not adequately treated, as well as being poorly understood. Clearly, there is a crucial need to develop improved strategies to understand the conditions that elicit suicidal behavior and to develop effective interventions.

Suicidal behavior is often, but certainly not always, associated with psychiatric illnesses, particularly major depression, bipolar disorder and schizophrenia. For example, a strong association was indicated by the finding that suicide is 60% comorbid with mood disorders,1 and the risk of suicide is at least 15 times higher in patients with bipolar disorder than for the general population.2 However, the perplexing question remains as to what differentiates the suicidal person from those with similar conditions that are not suicidal. This issue has led to numerous studies attempting to identify behavioral characteristics that contribute to suicidal behavior. Among the key characteristics that have been identified to be associated with suicidal behavior, impulsiveness, aggression and feelings of helplessness or depression demonstrate particularly strong links.1,3,9 These associations raise the possibility that identification of mechanisms and therapeutic interventions that regulate these characteristics may provide insight into the causes of suicidal behavior and lead to methods for early detection and intervention. In this regard, there is increasing evidence that abnormal activation of the inflammatory system is linked to each of these individual behaviors in animal models, and to suicidal behavior in humans.

Here, we review evidence suggesting that inflammation may be a key factor precipitating suicidal behaviors in response to initiating stressors, we assess key aspects of suicidal behavior-linked endophenotypes that have been studied in rodents, and we examine the effects of lithium intervention that appears to diminish suicide-linked behaviors.

STRATEGIES TO STUDY SUICIDAL BEHAVIOR IN ANIMAL MODELS

The very nature of suicide limits direct investigation except postmortem, thus gaining a better understanding of suicidal behavior requires the development of indirect strategies. Two feasible approaches include studies in animal models of mechanisms that regulate suicide-associated behaviors, and studies of the mechanism of action of drugs that alter suicidal behavior. Thus, although suicide cannot be directly studied in animal models, rodents can be used to study factors that regulate suicide-relevant behaviors or endophenotypes. Using the endophenotype approach to investigate complex behaviors associated with numerous psychiatric and neurological conditions has been discussed by many investigators in a variety of fields,6,10,11 and although not perfect, it remains the primary strategy available for studies in rodents. Thus, a better understanding of suicidal
behavior may benefit from studies of endophenotypes in rodents, particularly impulsive behavior, aggression and depression-like behaviors that have been linked to suicidal behavior. Another strategy to examine mechanisms regulating suicidal behavior is to consider the actions of an agent that reduces attempted and completed suicides. Substantial evidence demonstrates that lithium, the classical mood stabilizer used to treat bipolar disorder, reduces suicidal behavior and mortality during long-term treatment. This conclusion is supported by several meta analyses and has been reported in patients with unipolar and bipolar depression (the patient populations most often treated with lithium), in responders and nonresponders to the mood stabilizing action of lithium, and the antisuicidal effect of lithium is not matched by other mood stabilizers or antidepressants. Furthermore, several studies have found that relatively high levels of lithium in the public drinking water are associated with reduced risk of suicide in the general population. Thus, studies in rodents of individual behaviors associated with suicidal behavior, in conjunction with studies of lithium, which is able to diminish suicidal behavior, provide feasible investigative strategies to better understand the underlying causes of suicidal behavior and to develop effective interventions.

**STRESS INDUCES INFLAMMATION WHICH IS ASSOCIATED WITH SUICIDAL BEHAVIOR**

Stress is a common precursor of suicidal behavior. Stress also increases inflammation, and inflammation is linked to increased impulsive, aggressive and depressive behaviors, leading to the hypothesis that stress-triggered inflammation has an important role in provoking suicidal behavior (Figure 1). Multiple types of psychological stress have been shown to cause activation of the inflammatory response, which is indicated by elevated levels of inflammatory cytokines. However, comparative studies have not been reported to determine if different types of stress induce different patterns of inflammatory cytokine production, and which inflammatory molecules are most closely associated with suicidal behavior. The common finding that stress induces inflammation has been interpreted in evolutionary terms as a logical mechanism to enhance survival. Historically, many stressors had the potential to lead to injury and infection, therefore pre-activation of the immune system would enhance survival and recovery. However, as psychological stress has increased in modern societies, and drugs are available to combat life-threatening infections, these evolutionary mechanisms to improve survival after injury may now have deleterious effects on behaviors, including promotion of multiple suicide-linked behaviors, as discussed below.

Except for the initial insult, stress appears to utilize many of the same mechanisms as pathogens to induce an inflammatory response, although much still remains to be learned about the details of the stress-induced signaling pathway. The stress response is most well-characterized for signaling through Toll-like receptor 4 (TLR4), the receptor for lipopolysaccharide (LPS), which is the most widely used agent to study inflammation experimentally and is the major cause of sepsis. TLR4 is activated by both pathogen-associated molecular patterns of microbes, and insult-induced endogenous ligands, called danger- or damage-associated molecular patterns (DAMPs). DAMPs induce TLR4 signaling outcomes that respond to the need for rapid damage repair and restitution of homeostasis. DAMPs that activate TLR4 include a broad range of molecules, such as heat-shock proteins, hyaluronan oligosaccharides, high-mobility group protein box-1, modified lipids and several others, which are produced by a variety of stressors in the central nervous system as well as peripherally. Thus, stress-induced DAMPs can set in motion an inflammatory response that appears to be equivalent to that induced by pathogens. TLR4 is expressed by microglia, astrocytes and neurons, as well as immune cells. TLR4 expression is dynamic and is often upregulated in conditions that are associated with increased levels of pathogen-associated molecular patterns or DAMPs, including evidence of dynamic changes in the expression of TLR4 in the brain. For example, TLR4 expression in rodent brain increased in response to ischemia/reperfusion injury, which was partially attributed to DAMPs arising from oxidative stress. Furthermore, chronic mild stress increased TLR4 expression in rat prefrontal cortex, and administration of a TLR4 antagonist reduced stress-induced neuroinflammation. Thus, TLR4 can be activated in response to stress, not only by pathogens, and is involved in stress-induced inflammation, including in the central nervous system.

There is much evidence linking an activated inflammatory response with suicidal behavior. Elevated levels of inflammatory cytokines, particularly interleukin-6 (IL-6), were found in the blood and CSF of patients who attempted suicide compared with nonsuicidal depressed patients and controls. Elevated markers of inflammation and microglial activation also were found in postmortem brains of suicide victims. Conversely, therapeutic administration of cytokines to induce suicide risk is the most research. Particularly interesting is the recent finding from a postmortem brain study that protein expression of TLR4 is higher in depressed suicide victims than in depressed nonsuicide subjects and controls. Notably, alterations in genes involved in inflammation have been found to be associated with suicidal behavior in multiple studies of potential candidate genes. In addition, inflammation activates the enzyme indoleamine-2,3-dioxygenase, which catalyzes the formation of kynurenine, and plasma kynurenine levels were higher in depressed patients with a history of suicide attempts than in nonsuicidal depressed patients and healthy controls. The authors suggested that elevated kynurenine levels may be a marker of suicide attempt risk, independent of depression severity, and that kynurenine metabolites may serve as a source of additional research in this area.

**Figure 1.** Scheme of a potential mechanistic pathway that may lead to suicidal behavior. The scheme displays a hypothetical component of mechanisms contributing to suicidal behavior. Stress is established to cause activation of GSK3 in rodent brain, and lithium is an established inhibitor of GSK3, which we propose may contribute to its antisuicidal actions. Active GSK3 promotes inflammation, and we hypothesize that inflammation, one of multiple signaling systems regulated by GSK3, contributes to provoking components of suicidal behavior, such as aggression, impulsivity and depression. GSK3, glycogen synthase kinase-3.
contribute to the aggression/impulsivity and neurocognitive deficits proposed as endophenotypes associated with suicidal behavior.\(^1,18,77–79\) Thus, multiple lines of evidence demonstrate a consistent relationship between elevated markers of inflammation and suicidal behavior. Therefore, it is important to identify which components of suicidal behavior may be induced by activation of the inflammatory response.

**AGGRESSIVE BEHAVIOR**

Aggression has been linked to suicidal behavior in many studies\(^1,3,5,7,8,79\) and an increasing number of reports demonstrate that inflammation is associated with increased aggressive behaviors.\(^80\) Elevated aggressive traits were associated with increased serum TNF\(^\alpha\), with the inflammatory marker C-reactive protein,\(^92–94\) and with multiple cytokines.\(^84,85\) Increased serum IL-6 levels correlated with personality traits of aggression in healthy controls\(^83\) and with aggression traits in female patients with eating disorders.\(^86\) Furthermore, aggressive traits were increased in patients treated with cytokines therapeutically.\(^87,88\) Thus, in humans, aggressive behaviors are well correlated with increased markers of inflammation.

A few studies of rodents have also examined links between aggression and inflammation. In rodents, aggression is often measured using the social dominance tube test and the aggression test. Mice bred for high aggression had increased cytokine levels\(^80\) and knocked out of both tumor necrosis factor receptor-1 and tumor necrosis factor receptor-2 resulted in the remarkable absence of aggressive behavior.\(^90\) Thus, there appears to be a strong link between aggression and activation of the inflammatory system in rodents, but further studies are needed to verify this association and to delineate which inflammatory molecules mediate the interaction and the mechanisms that are involved.

Substantial evidence shows that lithium can reduce aggressive behavior. Lithium is well documented to reduce aggressive behavior in a variety of human populations, for example, children, adults and the elderly, which has been related to its antisuicidal actions.\(^1,4,5,7,8,78,103\) As reviewed in detail previously,\(^79\) many studies have shown that aggressive behavior in rodents also is consistently reduced by lithium treatment. Thus, lithium significantly reduces aggressive traits and inflammation, but these two outcomes of lithium administration have not yet been examined together.

**IMPULSIVE BEHAVIOR**

As noted in the Introduction, impulsive behavior may frequently be an important component of suicidal behavior. Only a limited number of studies have tested if there is a relationship between inflammation and impulsive behavior. In a study of nearly 5000 individuals, elevated levels of IL-6 were associated with impulsivity-related traits.\(^94\) A novel study of 5652 people over a period of 3 years identified a strong correlation between impulsiveness and increased lymphocyte numbers that are indicative of immune activation, and the authors concluded that ‘impulsiveness was a predictor of chronic inflammation’.\(^95\)

Links between inflammation and impulsive behavior appear not to have been examined in animal models, but there is evidence that lithium administration reduces impulsive behavior in humans and rodents. Three controlled studies of lithium in humans concluded that lithium reduces impulsive behavior, but further studies would strengthen this conclusion.\(^96–98\) In rodents, impulsive behavior exemplified by choosing a small or poor reward that is available immediately, in preference to a larger but delayed reward, is often measured using the three-choice serial reaction time task,\(^89\) in which mice are trained to respond to a flash of light occurring in one of three locations with a nose poke, which releases a food reward. In the subsequent test phase, mice are trained to choose between two light cues, one giving a larger food reward than the other. In subsequent trials, the delivery of the larger food reward is delayed, so mice must choose the immediate smaller reward or the delayed larger reward, and wild-type mice predominantly choose the latter. Increased impulsive behavior results in mice choosing the immediate smaller reward rather than the delayed larger reward. There is some indication that lithium treatment reduces impulsive behavior in rodents, but the data are limited. Lithium administration suppressed impulsive behavior in the three-choice serial reaction time task in male Wistar/ST rats, a strain that has been shown to be more impulsive than Lister hooded rats.\(^100\) Lithium reduced premature responses and increased the latency of the correct responses in the three-choice serial reaction time task in male Wistar/ST rats, without affecting response latency and without affecting the amount of food consumption or other motivation-related measures.\(^101\) Lithium also reduced impulsivity in mice in the delay discounting task in which mice receive larger rewards after a delayed response than after an immediate response.\(^102\) Thus, the links between impulsive behavior and inflammation, as well as its control by lithium, remain sparse but supportive of these associations.

**DEPRESSIVE BEHAVIOR**

Depression is often linked with suicidal behavior, although, in contrast to the commonly held assumption, many suicidal patients are not depressed.\(^1,4,5,7,8,78,103\) There is abundant evidence that inflammation is associated with the onset and severity of depression, as inflammatory molecules are upregulated in the serum and postmortem brains of depressed patients, as discussed in detail in several reviews.\(^104–109\) Furthermore, administration of interferon-α to bolster immunity induces depression in susceptible people.\(^103,110\) Moreover, LPS administration induces symptoms of depression in humans.\(^111\) and a mild stimulation of the primary host defense system has negative effects on emotion, which is thought to be caused by elevated cytokines.\(^110,112\) As noted above, psychological stresses that can induce depression increase inflammatory cytokine production in humans and rodents.\(^113,114\) Inflammation in patients with major depression is associated with resistance to antidepressant treatment, and anti-inflammatory drugs can improve antidepressant actions.\(^106–108,114–116\) Raison and Miller\(^116\) recently summarized results demonstrating that many genetic changes identified in patients with major depressive disorder involve the inflammatory system. In rodents, administration of inflammatory cytokines or the inflammation-stimulant LPS causes depression-like behaviors that are attenuated by antidepressants.\(^105\) Specific inflammatory cytokines that have been identified as promoters of depression-like behavior in rodents include IL-6,\(^117\) TNFα\(^118\) and IL-1β.\(^119\) Thus, there is much evidence that inflammation can precipitate depression and impair therapeutic responses.

Lithium is not used therapeutically as a direct antidepressant, but is often used to augment antidepressants in treatment-resistant depression, and inflammation is reduced by lithium. In mice, lithium has a wide variety of antidepressant-like effects. For example, in mice, lithium administration produces antidepressant-like effects in the learned helplessness paradigm\(^120\) and in the forced swim test.\(^121\) The antidepressant actions of lithium are often attributed to its action as an inhibitor of glycogen synthase kinase-3 (GSK3), as discussed in the following section, because pharmacological or molecular inhibition of GSK3 has similar antidepressant effects in animal models.

**GSK3 INHIBITORS REDUCE INFLAMMATION**

GSK3 refers to two paralogs, GSK3α and GSK3β, that are encoded by different genes but retain 85% homology and are commonly
referred to as isoforms. GSK3 is primarily regulated by phosphorylation on serine-21-GSK3α and serine-9-GSK3β, which inhibits GSK3 activity. Homozygous GSK3α/β21A/21A animals in mouse brain by stress,123 a response that may promote suicide-related behaviors. GSK3 is activated in regions and neural circuits that mediate each of the suicide-linked behaviors. Thus, we propose the concept that stress activates GSK3 and induces inflammation, which, in turn, promotes the suicide-linked endophenotypes of impulsivity, aggression and depression-like behaviors. GSK3 is expressed at normal levels.122 GSK3 may be a feasible therapeutic target to diminish suicidal behaviors because it promotes several suicide-linked behaviors in rodents and promotes inflammation, and lithium is a well-established inhibitor of GSK3, which may contribute to the capacity of lithium to reduce suicide risk.

A variety of evidence has raised the possibility that activated GSK3 may contribute to suicidal behaviors. GSK3 is activated in mouse brain by stress,123 a response that may promote suicide-linked behaviors, and GSK3β activity was found to be elevated in postmortem brains of depressed suicide victims.124 Clear evidence has demonstrated that GSK3 promotes aggressive behaviors, as reduced expression of either GSK3 isoform decreased aggressive behaviors in mice.124 In summary, GSK3 may be a feasible therapeutic intervention for suicidal behavior. GSK3 is activated by stress, is a strong promoter of inflammation, promotes in rodents aggressive and depression-like behaviors, and is inhibited by lithium, which diminishes suicidal behavior.

**PERSPECTIVE**

Altogether, there is substantial evidence that suicidal behavior and individual impulsivity, aggression and depression are all associated with increased inflammation, which itself can be induced by stress. Thus, we propose the concept that stress activates GSK3 and induces inflammation, which, in turn, promotes the suicide-linked endophenotypes of impulsivity, aggression and depression-like behaviors. We speculate that different inflammatory molecules are produced following different types of stress and that different inflammatory molecules may mediate each of the behavioral outcomes, perhaps accounting, in part, for why not all suicidal patients exhibit each behavior. Furthermore, it is likely that differential effects of inflammatory molecules on the specific brain regions and neural circuits that mediate each of the suicide-linked behaviors influence the cumulative behavioral outcome, which also must be regulated by genetic and epigenetic characteristics of affected subjects. Identification of the inflammatory and behavioral responses to stress that are attenuated by lithium may begin to provide information about its mechanism for reducing suicidal behavior, and why it is not effective in all patients. Furthermore, we suggest that inhibition of inflammatory signaling and inhibition of GSK3 may provide mechanisms to diminish in tandem both the inflammatory response to stress and suicide-related behaviors.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

**ACKNOWLEDGMENTS**

Research in the authors’ laboratories was supported by grants from the NIMH (MH038752, MH090236, MH095380).

**REFERENCES**

1 Mann JJ. Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003; 4: 819–828.
2 Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997; 170: 205–228.
3 Koller G, Preuss UW, Bottlender M, Wenzel K, Soyka M. Impulsivity and aggression as predictors of suicide attempts in alcoholics. Eur Arch Psychiatry Clin Neurosci 2002; 252: 155–160.
4 Joiner TE Jr, Brown JS, Wingate LR. The psychology and neurobiology of suicidal behavior. Annu Rev Psychol 2005; 56: 287–314.
5 Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies. Annu Rev Pharmacol Toxicol 2009; 49: 175–198.
6 Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients. Epidemiol Psychiatr Soc 2009; 18: 179–183.

This is mediated by GSK3 inhibition of the CREB and AP-1 transcription factors to reduce their expression of anti-inflammatory IL-10, which underlies the increase in IL-10 levels induced by GSK3 inhibitors.147,152 The anti-inflammatory actions of GSK3 inhibitors likely contribute to their beneficial effects that have been found in multiple animal models of inflammatory diseases, including endotoxic shock,147 arthritis and peritonitis,152 endotoxemia,144 endotoxic shock,147 arthritis and peritonitis,152 endotoxemia,144 colitis155 and traumatic brain injury.156 Furthermore, GSK3 inhibitors alleviate inflammatory disease severity in the mouse model of multiple sclerosis.146,157
13 Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. *Am J Psychiatry* 2005; 162: 1805–1819.

14 Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. *Bipolar Disord* 2006; 8: 625–639.

15 Guzzetta F, Tondo L, Centorrino F, Baldassarini RJ. Lithium reduces suicide risk in recurrent major depressive disorder. *J Clin Psychiatry* 2007; 68: 380–383.

16 Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. *BMJ* 2013; 346: f7646.

17 Vita A, De Peri L, Sacchetti E. Lithium in drinking water and suicide prevention: a review of the evidence. *Int Clin Psychopharmacol* 2014 (in press).

18 Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. *Philos Trans R Soc Lond B Biol Sci* 2003; 368: 20120537.

19 Nguyen KT, Deak T, Owens SM, Kohno T, Fleschner M, Watkins LR et al. Exposure to acute stress increases brain interleukin-1beta protein in the rat. *Neuroscience* 1998; 22: 1239–2246.

20 Nguyen KT, Deak T, Will MJ, Hansen MK, Hunsaker BN, Fleshner M et al. Time-course and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1beta protein response to acute stress. *Brain Res* 2000; 859: 193–201.

21 Quan N, Avitsur R, Stark JL, He L, Shah M, Caliguri M et al. Social stress increases the susceptibility to endotoxic shock. *J Neuroimmunol* 2001; 115: 36–45.

22 Johnson JD, O’Connor KA, Deak T, Stark M, Watkins LR, Maier SF et al. Prior stressor exposure sensitizes LPS-induced cytokine production. *Brain Behav Immun* 2002; 16: 461–476.

23 Madrigal JL, Hurtado O, Moro MA, Lizaoido I, Lorenzo P, Castrillo A et al. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. *Neuropsychopharmacology* 2002; 26: 155–163.

24 Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D et al. Stress-induced sensitization of proinflammatory cytokine response to acute stress. *J Neuroimmunol* 2003; 142: 155–162.

25 Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. *Bipolar Disord* 2006; 8: 625–639.

26 Kiecolt-Glaser JK, Preacher KJ, MacCallum RC, Atkinson C, Malarkey WB, Glaser R et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. *Bipolar Disord* 2006; 8: 625–639.

27 Audet RJ, Auerbach LS, Fehm HL, Madison S et al. Lithium modulates suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. *Am J Psychiatry* 2005; 162: 1805–1819.

28 Audet R, Jacobson-Pick S, Wann BP, Anisman H. Social defeat promotes specific cytokine variations within the prefrontal cortex upon subsequent aggressive or endotoxin challenges. *Brain Behav Immun* 2011; 25: 1197–1205.

29 Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. *Nat Rev Immunol* 2011; 11: 625–632.

30 Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH et al. Social stress enhances IL-1B and TNF-a production by Porphyromonas gingivalis lipopolysaccharide-stimulated CD11b+ cells. *Physiol Behav* 2009; 98: 351–358.

31 Blundell P, Barnum CJ, Solomon LG, Lankow BS, Deak T et al. Gene expression changes in the hypothalamus provide evidence for regionally-selective changes in IL-1 and microglial markers after acute stress. *Brain Behav Immun* 2009; 23: 958–969.

32 Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H et al. Activation of the TLR4-MyD88 pathway during acute stress enhances inflammatory cytokine expression in the hypothalamus. *Neuropsychopharmacol Biol Psychiatry* 2013; 38: 978–996.

33 Gareta I, Garcia-Bueno B, Madrigal JL, Bravo L, Berrocoso E, Caso JR et al. Origin and consequences of brain Toll-like receptor 4 pathway stimulation in an experimental model of depression. *J Neuroinflammation* 2011; 8: 15–37.

34 Gareta I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, Gomez-Lus ML et al. Stress-induced neuroinflammation: role of the Toll-like-receptor 4 pathway. *Biol Psychiatry* 2013; 73: 32–43.

35 McQuaid RJ, Audet MC, Jacobson-Pick S, Anisman H. Environmental enrichment influences brain cytokine variations elicited by social defeat in mice. *Psychoneuroendocrinology* 2013; 38: 977–986.

36 Gareta I, Garcia-Bueno B, Madrigal JL, Caso JR, Alou L, Gomez-Lus ML et al. Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress. *J Neuroinflammation* 2014; 11: 8.

37 Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). *Mol Psychiatry* 2013; 18: 15–37.

38 Akira S. TLR signaling. *Curr Top Microbiol Immunol* 2006; 311: 1–16.

39 Okun E, Griffin KC, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. *Trends Neurosci* 2011; 34: 269–281.

40 Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H et al. SSPo7 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. *J Biol Chem* 2002; 277: 15107–15112.

41 Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. *Nat Med* 2005; 11: 1173–1179.

42 Yang QW, Lu FL, Zhou Y, Wang L, Zhang Q, Lin S et al. HMGB1 mediates ischemia-reperfusion injury by TRIF-adaptor independent Toll-like receptor 4 signaling. *J Leuc Biol* 2010; 113: 603–605.

43 Gill R, Tsung A, Billiar T. Linking oxidative stress to inflammation: Toll-like receptors. *Free Radic Biol Med* 2010; 48: 1121–1132.

44 BSBi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. *J Neuropathol Exp Neurol* 2002; 61: 1013–1021.

45 Olson JK, Miller SD. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. *J Immunol* 2004; 173: 3916–3924.

46 Tang SC, Arumugam T, Xu X, Cheng A, MugHAL MR, Jo DG et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. *Nat Neurol Sci* 2008; 4: 1077–1086.

47 Snoa JA, BliTz D, Margolin Z, Vartanian T. A clear and present danger: endogenous ligands of Toll-like receptors. *Neuromolecular Med* 2010; 25: 48–109.

48 Van Noort JM, BiSBi M. Toll-like receptors in the CNS: implications for neurodegeneration and repair. *Prog Brain Res* 2009; 173: 139–148.

49 Lehnardt S, Lehmann S, Kauf D, Tschimmel K, Hoffmann O, Cho S et al. Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia. *J Neuromolecular Med* 2007; 1: 90–92.

50 Nääsälder L, Träskman-Bendz L. Increased soluble interleukin-2 receptor concentrations in suicide attempters. *Acta Psychiatr Scand* 1993; 88: 49–52.

51 Kim YK, Lee SW, Kim SH, Shin SH, Han SW, Choi SH et al. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32: 356–361.

Inflammation and lithium modulate suicidal behavior E Beurel and RS Jope

Translational Psychiatry (2014), 1–7
62 Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. *Biol Psychiatry* 2009; 66: 287–292.

63 Janelidze S, Mattel D, Westrin A, Traskman-Bendtz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. *Brain Behav Immun* 2011; 25: 335–339.

64 Lindqvist D, Janelidze S, Erhardt S, Traskman-Bendtz L, Engström G, Brundin L et al. CSF biomarkers in suicide attempters—a principal component analysis. *Acta Psychiatr Scand* 2011; 124: 52–61.

65 Steiner J, Bielau H, Birsch R, Danos P, Ullrich O, Marwim C et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. *J Psychiatr Res* 2008; 42: 151–157.

66 Tonelli LH, Stillier J, Rujescu D, Giegling I, Schneider B, Maurer K et al. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. *Acta Psychiatr Scand* 2008; 117: 198–206.

67 Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC et al. Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. *J Psychiatr Res* 2012; 46: 57–63.

68 Barond DA, Hardie T, Baron SH. Possible association of interleukin-2 treatment with depression and suicide. *J Am Osteopath Assoc* 1993; 93: 799–800.

69 Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with α-interferon therapy for chronic viral hepatitis. *J Hepatol* 1994; 21: 241–243.

70 Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willenbring ML et al. Suicide ideation during interferon-α2b and ribavirin treatment of patients with chronic hepatitis C. *Gen Hosp Psychiatry* 2004; 26: 237–240.

71 Fragoso YD, Frota ER, Lopes JS, Noal JS, Giacomo MC, Gomes S et al. Major depression. *Mol Psychiatry* 2010; 15: 119–126.

72 Sequeira A, Klempan T, Canetti L, ffrench-Mullen J, Benkelfat C, Rouleau GA et al. Patterns of gene expression in the limbic system of suicides with and without major depression. *Mol Psychiatry* 2007; 12: 640–655.

73 Thalmeier A, Dickmann M, Giegling I, Schneider B, Hartmann M, Maurer K et al. Gene expression profiling of post-mortem orbitofrontal cortex in violent suicide victims. *Int J Neuropsychopharmacol* 2008; 11: 217–228.

74 Galfalvy H, Zalsman G, Huang YY, Murphy L, Rosoklija G, Dwork AJ et al. A pilot genome wide association and gene expression array study of suicide with and without major depression. *World J Biol Psychiatry* 2013; 14: 574–582.

75 Sublette ME, Galfalvy HC, Fuchs D, Lapidus M, Grunebaum MF, Quemado MA et al. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. *Brain Behav Immun* 2011; 25: 1272–1278.

76 Mann JJ, Currier DM. Stress, genetics and epigenetic effects on the neurobiology of suicidal behaviour and depression. *Eur Psychiatry* 2010; 25: 268–271.

77 Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton P et al. Candidate endophenotypes for genetic studies of suicidal behavior. *Biol Psychiatry* 2009; 65: 556–563.

78 Zalcman SS, Siegel A. Neurobiology of aggression and rage: role of cytokines. *Brain Behav Immun* 2006; 20: 507–514.

79 Suarez EC, Lewis JG, Kuhn C. The relation of aggression, hostility, and anger to psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. *J Clin Psychiatry* 2003; 64: 708–714.

80 Petitto JM, Lysle DT, Gariepy JL, Lewis MH. Association of genetic differences in social behavior and cellular immune responsiveness: effects of social experience. *Brain Behav Immun* 1994; 8: 111–122.

81 Patel A, Siegel A, Zalakas SS. Lack of aggression and anxiolytic-like effect in TNF receptor (TNF-R1 and TNF-R2) deficient mice. *Brain Behav Immun* 2010; 24: 1276–1280.

82 Bierbrauer J, Nilsson A. Müller-Oerlinghausen B. Bauer M. Therapeutic and prophylactic effects of lithium on pathological aggression. In: Bauer, M, Grof, P, Müller-Oerlinghausen, B (eds). *Lithium in Neuropsychiatry*. Informa Healthcare, Abingdon, UK, 2006. 227–236.

83 Kovacsics CE, Gould TD. Shock-induced aggression in mice is modified by lithium. *Pharmacol Biochem Behav Biochem* 2010; 94: 380–386.

84 O'Donnell KC, Gould TD. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. *Neurosci Biobehav Rev* 2007; 31: 932–962.

85 Sutin AR, Terracciano A, Deiana B, Naizta S, Ferrucci L, Uda M et al. High neuroticism and low conscientiousness are associated with interleukin-6. *Psychol Med* 2010; 40: 1485–1493.

86 Sutin AR, Milaneschi Y, Canassas A, Ferrucci L, Uda M, Schlessinger D et al. Impulsivity-related traits are associated with higher white blood cell counts. *J Behav Med* 2012; 35: 616–623.

87 Orrego MF, Canavero L, Kuzis G, Sabe L, Starkstein S. A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings. *J Neuropsychiatry Clin Neurosci* 2006; 18: 199–206.

88 Swann AC, Bowden CL, Calabrese JR, Dilavser SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. *Neuropsychopharmacology* 2002; 26: 530–536.

89 Hollander E, Pallanti S, Allen A, Sood E, Baldini Rossi N. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders? *Am J Psychiatry* 2005; 162: 137–145.

90 Higgins GA, Breysses N. Rodent model of attention: the S-choice serial reaction time task. *Curr Protoc Pharmacol* 2008; Chapter 5, Unit 5.49.

91 Galtress T, Garcia A, Kirkpatrick K. Individual differences in impulsive choice and timing in rats. *J Exp Anal Behav* 2012; 98: 65–87.

92 Ohmura Y, Tsutsui-Kimura I, Kumamoto H, Minami M, Izumi T, Yamaguchi T et al. Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats. *Psychopharmacology* 2012; 219: 421–432.

93 Halcombe ME, Gould TD, Grahame NJ. Lithium, but not valproate, reduces impulsive choice in the delay discounting task in mice. *Neuropsychopharmacology* 2013; 38: 1937–1944.

94 Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuropsychiology. *Neuropsychopharmacology* 2005; 35: 240–248.

95 Schiepers OJ, Wichts MC, Maes M. Cytokines and major depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2005; 29: 201–217.

96 Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. *Brain Behav Immun* 2007; 21: 153–160.

97 Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci* 2008; 9: 46–56.

98 Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol Psychiatry* 2009; 65: 734–741.

99 Rivest S. Regulation of innate immune responses in the brain. *Nat Rev Immunol* 2009; 9: 429–439.

100 Shelton RC, Claiborne J, Sidoryk-Wegrzynowicz M, Reddy R, Aschner M, Lewis DA et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. *Mol Psychiatry* 2011; 16: 751–762.

101 Loirich FE, Ferrell RE, Rabinovitz M, Pollock BG. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. *JAMA Psychiatry* 2009; 65: 344–348.

102 Kullmann IS, Gregoire JS, Lichte P, Kobb P, Rosenberger C, Banner C et al. Neural response to emotional stimuli during experimental human endotoxemia. *Hum Brain Map* 2013; 34: 2127–2227.

103 Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. *Arch Gen Psychiatry* 2001; 58: 445–452.

104 Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. *Ann Med* 2003; 35: 2–11.
Gabbay V, Klein RG, Alonso CM, Babbs JS, Nishawala M, De Jesus G et al. Immune system dysregulation in adolescent major depressive disorder. *J Affect Disord* 2009; 115: 177–182.

O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. *J Psychiatr Res* 2007; 41: 326–331.

Roumestant C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C et al. Anti-inflammatory properties of desipramine and fluoxetine. *Respir Res* 2007; 8: 3–15.

Chourbaji S, Urani A, Inta I, Sanchis-Segura C, Brandwein C, Zink M et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. *Neurobiol Dis* 2006; 23: 587–954.

Simen BB, Duman CH, Simen AA, Duman RS. TNFα. *Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy between GSK3β produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol* development.

Role of GSK3β in behavioral abnormalities induced by serotonin de-2

Estimation of glycogen synthase kinase-3β gene and increased impulsivity in bipolar disorder. *Biol Psychiatry* 2004; 61: 1568–1670.

O'Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S. Between GSK3β produces antidepressant-like effects in the forced swim test. *Int J Neuropsychopharmacol*

Glycogen synthase kinase-3β in hippocampus. *BiocJ Basic 2008; 150: 510–518.

Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. *Front Mol Neurosci* 2011; 4: 16–26.

Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C. Produces antidepressant-like effects in the forced swim test.

Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS et al. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. *Neuropsychopharmacology* 2004; 29: 1426–1431.

Klein PS, Metlon DA. A maleate mechanism for the effect of lithium on development. *Proc Natl Acad Sci USA* 1996; 93: 8455–8459.

Simen BB, Duman CH, Simen AA, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy between GSK3β produces antidepressant-like effects in the forced swim test. *Int J Neuropsychopharmacol* development.

Role of GSK3β in behavioral abnormalities induced by serotonin de-2

Estimation of glycogen synthase kinase-3β gene and increased impulsivity in bipolar disorder. *Biol Psychiatry* 2004; 61: 1568–1670.

O'Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S. Between GSK3β produces antidepressant-like effects in the forced swim test. *Int J Neuropsychopharmacol*

Glycogen synthase kinase-3β in hippocampus. *BiocJ Basic 2008; 150: 510–518.

Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. *Front Mol Neurosci* 2011; 4: 16–26.

Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. *Int J Neuropsychopharmacol* 2004; 7: 387–390.

Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like effects in the forced swim test. *Int J Neuropsychopharmacol* 2004; 7: 387–390.

Shapira M, Licht A, Milman A, Pick CG, Eldar-Finkelman H et al. Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury. *Mol Cell Neurosci* 2007; 34: 571–577.

Silva R, Mesquita AR, Bessa J, Sousa JC, Sotnikova TD, Cools MJ, Wetsel WC et al. Role of GSKβ in behavioral abnormalities induced by serotonin deficiency. *Proc Natl Acad Sci USA* 2008; 105: 1333–1338.

Kaidanovich-Beilin O, Lipina TV, Takao K, van Eede M, Hattori S, Laliberté C et al. Abnormalities in brain structure and behavior in GSK3α mutant mice. *Mol Brain* 2009; 2: 35.

Jiménez E, Arias B, Mitjans M, Goikolea JM, Roda E, Ruiz V et al. Association between GSK3β gene and increased impulsivity in bipolar disorder. *Eur Neuropsychopharmacol* 2014; 24: 510–518.

Jope RS. Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. *Front Mol Neurosci* 2011; 4: 16–26.

Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. *Int J Neuropsychopharmacol* 2004; 7: 387–390.

Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H. Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus. *BiocJ Psychi* 2004; 55: 781–784.

Shapira M, Licht A, Milman A, Pick CG, Shohami E, Eldar-Finkelman H et al. Role of glycogen synthase kinase-3β in early depressive behavior induced by mild traumatic brain injury. *Mol Cell Neurosci* 2007; 34: 571–577.

Silva R, Mesquita AR, Bessa J, Sousa JC, Sotnikova TD, Lelo P et al. Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen synthase-kinase-3β. *Neuroscience* 2008; 152: 656–669.

Willkinson MB, Dias C, Magda J, Mazié-Robison M, Lobo M, Kennedy P et al. A novel role of the WNT-dishevelled-GSK3β signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. *J Neurosci* 2011; 31: 9084–9092.

Okamoto H, Voleti B, Banasr M, Sarhan M, Duric V, Girgenti M. J et al. Win2 expression and signaling is increased by different classes of antidepressant treatments. *Biol Psychiatry* 2010; 68: 521–527.

Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS et al. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. *Neuropsychopharmacology* 2004; 29: 1426–1431.

Klein PS, Metlon DA. A maleate mechanism for the effect of lithium on development. *Proc Natl Acad Sci USA* 1996; 93: 8455–8459.